Comparative Pharmacology
Head-to-head clinical analysis: FLAGYL I V versus METRONIDAZOLE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAGYL I V versus METRONIDAZOLE HYDROCHLORIDE.
FLAGYL I.V. vs METRONIDAZOLE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
Upon anaerobic reduction of the nitro group, forms toxic intermediates that damage bacterial DNA and inhibit nucleic acid synthesis.
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
Intravenous: 500 mg every 6 hours or 500 mg every 8 hours. Typical adult dose: 500 mg IV every 6 hours.
None Documented
None Documented
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
7-8 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment.
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
Renal 60-80% as unchanged drug and metabolites; fecal 6-15%; biliary minor.
Category C
Category A/B
Nitroimidazole Antibiotic
Nitroimidazole Antibiotic